PerkinElmer and Eppendorf AG Announce Co-Marketing Agreement for Microarray Solutions
PerkinElmer, Inc. (NYSE: PKI), a global leader in health sciences, and Eppendorf AG, a leading supplier of systems and research tools for the biotechnology industry worldwide, announced today the signing of a co-marketing agreement to jointly promote microarray technology that combines Eppendorf’s DualChip content arrays with PerkinElmer’s ScanArray™ GX Microarray Analysis System. The announcement was made at the Chips to Hits industry event being held September 12-14, 2005, in Boston.
The combination of the novel DualChip technology, consisting of 2 identical arrays on a single slide, and the user-friendly scanning protocols of ScanArray GX provides a complete solution, from array processing to data analysis. The PerkinElmer/Eppendorf microarray solution is ideal for a wide range of applications, including medical, clinical and biotechnology research.
“Our scanners, combined with the optimized protocols for Eppendorf’s new chip technologies, will deliver reliability and simplicity to customers,” said Peter Coggins, PhD., president, PerkinElmer Life and Analytical Sciences. “For each DualChip, Eppendorf will provide exact protocols to allow customers to set-up and optimize their assays on PerkinElmer scanners, thereby offering considerable advantages and significantly increasing efficiency.”
“With PerkinElmer and Eppendorf’s combined array expertise, committed scientists can now use an array as a personal tool that fits the budget,” stated Dr. Thomas Kolzau, director of the Microarray Systems Product Group at Eppendorf AG. Only recently Eppendorf AG had been conferred the 2005 Frost & Sullivan Technology Innovation Award in recognition for its unique contribution by proactively leveraging its new DualChip Microarray technology to molecular technologies towards possible drug discovery and clinical research applications. According to Frost & Sullivan’s findings, microarrays have been widely demonstrated to empower researchers working in drug discovery and clinical research through the expression profiling method.
About PerkinElmer
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Industrial Sciences markets to improve the quality of life. The Company reported revenues of $1.7 billion in 2004, has 10,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
About Eppendorf AG
Eppendorf AG is based in Hamburg, Germany. In the 2004 financial year, Eppendorf employed 1,748 people worldwide and achieved sales of 287 million Euro (approx. 345 million US Dollars) with an operative result (EBIT) of 40.1 million Euro (approx. 48 million US Dollars).
